Targeting these nanocarriers to common glioma-specific markers, such as Ephrin A2 (EphA2) [57], epidermal growth factor receptor (EGFR), and others [58], might further improve personalized specificity and accumulation. The gene discussed is EGFR; the disease is central nervous system cancer.